These findings suggest that TREM1 regulates the PMT process in GBM patients through the TLR4/PI3K/AKT/mTOR signaling axis, positioning TREM1 as a promising target for improving therapeutic outcomes in glioma patients. This evidence concerns the gene TLR4 and glioma.